Skip to content
    MDLN
    Earnings call· Jun 2026(Q2 FY26)

    Medline Q2 FY26 earnings call MDLN

    Aug 5, 2026 Source

    Executive summary

    Medline Q2 FY26 — Strong Top-Line Growth Offset by Margin Headwinds and Strategic Investments

    Medline delivered robust top-line growth in Q2 FY26, driven by strong organic performance and new customer acquisitions, leading to a second upward revision of its full-year sales outlook. However, the company faces significant margin pressures from the Tracy fire, increased operational and quality investments, and retail channel softness, resulting in a lowered adjusted EBITDA guidance. Management emphasizes strategic investments for long-term growth and competitive positioning, while actively pursuing cost savings and evaluating future pricing actions to restore margin profiles.

    Highlights

    5

    • Net sales increased 12% year-over-year to $7.7 billion, driven by organic growth.

    • Organic sales guidance for FY26 raised for the second time to 9%-10% from 8.5%-9.5%.

    • New customer signings reached over $650 million in the first half, representing over 65% of the $1 billion annual goal.

    • Adjusted EBITDA increased 13% year-over-year to $1.1 billion, including a $243 million net IEEPA tariff refund benefit.

    • Net leverage reduced to 2.9x, achieving the long-term goal of less than 3x.

    Concerns

    5

    • Full year adjusted EBITDA guidance lowered to $3.3 billion-$3.4 billion from $3.5 billion-$3.6 billion.

    • Tracy distribution center fire resulted in $336 million in net income reduction (excluded from adjusted EBITDA), with an additional $50 million-$100 million in costs expected in H2 2026.

    • Retail channel softness impacted Front Line Care and U.S. non-acute sales and margins, expected to remain a headwind.

    • Increased operational investments and quality remediation efforts are creating near-term inefficiencies and margin pressure.

    • Middle East conflict contributing to higher-than-expected inflationary pressure, estimated at $70 million for FY26.

    Guidance & targets

    6
    CategoryTargetConfidence
    Full year organic sales growth
    9% to 10%
    high materiality
    High
    Full year adjusted EBITDA
    $3.3 billion to $3.4 billion
    high materiality
    Medium
    Full year 2026 net tariff impacts
    approximately $350 million
    medium materiality
    High
    Full year tax distributions
    $250 million to $300 million
    low materiality
    High
    Full year CapEx
    $500 million to $600 million
    medium materiality
    High
    Adjusted EBITDA growth rate
    at or above the rate of sales growth
    high materiality
    Medium

    Segment performance

    8
    SegmentRevenueYoYQoQMargin
    Medline Brands
    Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 3 percentage points. First half net sales were $7 billion, up 6% YoY.
    		$3.5 billion7%——
    Surgical Solutions
    Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 3 percentage points. Strong growth driven by surgical kitting. First half net sales were $3.2 billion, up 8% YoY.
    		$1.6 billion9%——
    Front Line Care
    Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 3 percentage points. Strong demand in exam gloves and personal care, partially offset by unplanned retail channel softness. First half net sales were $3.3 billion, up 5% YoY.
    		$1.7 billion4%——
    Lab and Diagnostics
    Driven by new customer implementations and existing customer demand, including strong core acute care lab growth from multichannel prime vendor agreements. First half net sales were $541 million, up 6% YoY.
    		$248 million12%——
    Supply Chain Solutions
    Supported by new customer implementations and growth with existing customers, expanding opportunity for Medline brand conversion. First half net sales were $8 billion, up 16% YoY. Margin impacted by year 1 rebates and operational investments.
    		$4.1 billion16%—4.9% adjusted EBITDA margin
    U.S. Acute Care
    Driven by new Prime Vendor customers and existing customer growth. Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 1 percentage point. First half net sales were $10.5 billion, up 13% YoY.
    		$5.4 billion15%——
    U.S. Non-Acute Care
    Growth primarily driven by existing customers and new customer signings in physician office and post-acute channels, partially offset by retail softness. Customer repayments tied to IEEPA tariff refunds reduced growth by approximately 2 percentage points. First half net sales were $3.5 billion, up 5% YoY.
    		$1.7 billion4%——
    International
    Driven by volume growth in Canada and Europe. First half net sales were $1 billion, up 10% YoY.
    		$533 million9%——

    Operational metrics

    19
    Net sales
    $7.7 billionup 12% YoY
    Q2 FY26

    Driven primarily by organic growth.

    Adjusted EBITDA
    $1.1 billionup 13% YoY
    Q2 FY26

    Partially offset by higher cost of goods sold, increased operational expenses, and net tariff release impacts.

    Adjusted EBITDA margin
    13.8%increased 20 bps
    Q2 FY26

    Year-over-year.

    Net income reduction from Tracy fire
    $336 million
    Q2 FY26

    Primarily reflecting inventory and fixed asset losses and other related costs. Excluded from adjusted EBITDA. Sufficient insurance coverage expected.

    CapEx
    $207 million
    First 6 months FY26

    Reflecting investments in distribution center enhancements, automation, and capacity expansion of Mexico citing facility.

    Cash and cash equivalents
    $2.3 billion
    Q2 FY26

    Balance at quarter end.

    Short-term investments
    $350 million
    Q2 FY26

    Balance at quarter end.

    Net leverage
    2.9x
    Q2 FY26

    Achieved long-term goal of less than 3x.

    New customer signings
    $650 million
    First half FY26

    Representing over 65% of the annual goal.

    Tracy-related costs (expected)
    $50 million to $100 million
    H2 FY26

    Additional costs expected in the second half of 2026.

    Middle East conflict estimated impact
    $70 million
    FY26

    Estimated expected impact for 2026, mostly offset by tariff benefits.

    Adjusted EBITDA underlying performance (excluding tariff benefit)
    $870 million
    Q2 FY26

    True underlying performance for Q2 FY26, excluding the $243 million net IEEPA tariff refund benefit.

    Total tariff refund available
    $507 million
    Cumulative

    Total amount of IEEPA tariff refund available to Medline.

    Net tariff benefit recorded (H1 FY26)
    $240 million
    H1 FY26

    Recorded in financials for the first half of the year.

    Customer repayment for IEEPA tariffs
    $89 million
    FY26

    Full amount of customer repayment for IEEPA tariffs, booked as an accrual, expected to be paid in latter part of the year. Included in sales guidance.

    Total tariff headwinds
    $230 million
    FY26 YTD

    Total tariff headwinds experienced so far in 2026.

    Incremental earnings impact (guidance change)
    50% transitory / 50% permanent
    FY26

    Roughly half of the incremental earnings impact from guidance change is transitory, half is permanent and will become part of future cost base.

    Incremental costs (Q3/Q4 split)
    1/3 in Q3, 2/3 in Q4
    H2 FY26

    Expected distribution of $200 million incremental costs for the remainder of the year.

    California distribution footprint
    nearly 5 million square feet
    by mid-2027

    Expected footprint by mid-2027, including new facilities following the Tracy fire and a new Southern California DC.

    Industry KPIs

    5
    MetricValueDetails
    Tariff impact$243 millionUSD
    Pricing realized pricereduced growth by approximately 1 percentage point%
    Procedure volume growthlift
    FCF conversion leverage guidance2.9x
    Sales force commercial capacity buildrealigned

    Deals & partnerships

    1
    Allina HealthExpanded prime vendor agreement

    Expanded presence in the Upper Midwest, covering acute care and physician office settings. Went live about 3 weeks prior to the call.

    Risks & headwinds

    6
    Tracy distribution center fire costsQ2 FY26 and H2 FY26

    $336 million net income reduction in Q2 FY26; additional $50 million-$100 million expected in H2 FY26

    Mitigation: Leveraging existing inventory and distribution network, securing 1.6 million sq ft of new DC space, expected insurance recoveries.

    Middle East conflict inflationary pressureFY26

    Estimated $70 million impact for FY26 (fuel, product costs)

    Mitigation: Absorbing costs to maintain customer relationships and gain share, leveraging cross-sourcing relationships, monitoring situation.

    Increased operational investmentsNear-term

    Contributing to 75% of incremental earnings impact (internal factors)

    Mitigation: Investing in staffing, technology, and scaling efforts to meet demand; adding new distribution centers to drive future efficiencies.

    Quality remediation effortsNear-term

    Contributing to 75% of incremental earnings impact (internal factors); products taking longer to reintroduce to market (e.g., CHG lives)

    Mitigation: Enhancing quality organization, investing in manufacturing network, proactive engagement with FDA on global quality action plan.

    Retail channel softnessBalance of the year

    Impacting Front Line Care and U.S. non-acute sales and margins; contributing to 75% of incremental earnings impact (internal factors)

    Mitigation: Realigning sales organization around retail customers and their specific needs, working to earn back lost business.

    Tariff rate changesFY26 and FY27

    Full year 2026 net tariff impacts estimated at $350 million (down from $490 million); any further changes immaterial for 2026 but affect 2027

    Mitigation: Leveraging significant inventory on hand to mitigate immediate impact, monitoring fluid situation.

    What to watch in Q3 FY26

    5

    Retail channel performance

    next quarter
    CurrentSoftness impacting Front Line Care and U.S. non-acute sales
    TargetImprovement in sales and margins, successful regaining of lost business

    Why it matters

    Retail softness disproportionately impacts Medline brand profitability and is a key internal headwind.

    While we are taking steps to improve retail, we expect it to remain a headwind for the balance of the year.

    Q&A highlights

    6

    Is overspending on growth part of the strategy for share gains, and what market conditions are needed to return to EBITDA growth above revenue growth?

    Management confirmed that investing ahead of growth is a long-standing strategy, citing investments in distribution centers, manufacturing, and sales teams. They are happy with underlying performance and expect continued strength. Returning to EBITDA leverage requires continued execution on operational investments, quality remediation, and new customer signings.

    “If you think about our business, we've been intentional for many, many years of investing in our business for growth ahead of the growth.”

    asked by Michael Cherny · answered by Michael Drazin

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Commercial Execution and Customer Signings

    Medline achieved significant commercial momentum in Q2 FY26, securing over $650 million in new customer signings in the first half, tracking ahead of its $1 billion annual goal. These wins span across various channels including acute care, physician office, lab, skilled nursing, senior living, home health, and hospice, demonstrating the company's ability to gain market share. A notable win was an expanded prime vendor agreement with Allina Health in the Upper Midwest, covering acute care and physician office settings.

    02

    Response to Tracy Distribution Center Fire

    The company demonstrated resilience in responding to the mid-June fire at its Tracy, California distribution center. Leveraging its broad distribution network and inventory, Medline minimized customer disruption. Within a month, 1.6 million square feet across two new distribution centers were secured, expanding the Northern California footprint by 45%. The new Tracy DC is expected to serve customers in Q4, and a new stocking facility in January 2027, reinforcing supply chain resiliency.

    03

    Strategic Infrastructure Investments

    Beyond the Tracy fire recovery, Medline announced plans for a new 1 million square foot distribution center in Southern California, aiming to reach nearly 5 million square feet across California by mid-2027. These investments in new facilities and automation technologies are designed to enhance supply chain flexibility, redundancy, and capacity, supporting future growth and anticipating customer demand. The company views these as crucial for maintaining its position as a vertically integrated manufacturer and distributor.

    04

    Quality Remediation and Operational Investments

    Medline is undertaking significant remediation activities to strengthen its quality organization and manufacturing processes, proactively engaging with the FDA on a global quality action plan. These investments include people, processes, and technology, accelerating initiatives to support growth. The company also modified its complaint review process, expecting an increase in medical device reporting (MDR) submissions in the second half, reflecting enhanced vigilance.

    05

    Retail Channel Softness and Strategic Realignment

    The retail business, representing less than 2% of overall sales but almost entirely Medline brand, experienced unplanned softness, impacting Front Line Care and U.S. non-acute sales and margins. This was attributed to the loss of a portion of a customer due to a lack of understanding of customer needs. In response, Medline has realigned its sales organization to better support retail customers and improve competitiveness, aiming to regain lost business despite the channel's inherent volatility.

    06

    Tariff Impacts and Pricing Strategy

    The company recorded a net IEEPA tariff refund benefit of $243 million in Q2, which was excluded from adjusted EBITDA guidance to show underlying performance. Full-year net tariff impact🌐s are now estimated at $350 million, down from $490 million previously. Medline has chosen to absorb inflationary pressures from the Middle East conflict and other costs rather than broadly pass them to customers, aiming to maintain long-term relationships and gain market share, while reserving pricing as a future option once cost impacts stabilize.

    AI-generated summary of the company’s earnings call. Not investment advice.